| Title | A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China |
| Authors | Jiang, Qian Li, Zongru Qin, Ya-Zhen Zhao, Ting Liu, Bingcheng Chen, Zi Niu, Qian Men, Lichuang Wang, Hengbang Yang, Dajun Zhai, Yifan Huang, Xiao-Jun |
| Affiliation | Peking Univ, Inst Hematol, Peoples Hosp, Beijing, Peoples R China Chinese Acad Med Sci, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis,Leukemia Ctr, Tianjin, Peoples R China HealthQuest Pharma Inc, Guangzhou, Peoples R China Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China Ascentage Pharma Grp Inc, Rockville, MD USA Healthquest Pharma Co Ltd, Guangzhou, Peoples R China |
| Issue Date | 15-Nov-2022 |
| Publisher | BLOOD |
| URI | http://hdl.handle.net/20.500.11897/670837 |
| ISSN | 0006-4971 |
| DOI | 10.1182/blood-2022-170868 |
| Indexed | CPCI-S(ISTP) SCI(E) |
| Appears in Collections: | 医学部待认领 |
